HeartFlow Files Patent Suit Against Cleerly

Context

HeartFlow filed a patent infringement lawsuit against Cleerly on April 13, 2026, according to a report from Investing.com (Apr 13, 2026). The complaint centers on coronary artery disease (CAD) diagnostic technology that both companies commercialize: HeartFlow for CT-based physiological flow analysis and Cleerly for image-based atherosclerotic plaque and stenosis quantification. Legal filings frame the dispute as an issue of proprietary algorithms and downstream clinical decision support, with HeartFlow asserting that its intellectual property underpins key components of Cleerly’s CAD product set. The move escalates competitive tensions in a narrow but strategically important segment of cardiology diagnostics at a time when payors and health systems are scrutinizing value and outcomes more intensely.

The timing is material. The complaint was publicized on April 13, 2026 (Investing.com, Apr 13, 2026), and comes after several years of broader adoption of coronary CT angiography (CCTA) and computed tomography-derived fractional flow reserve (FFRct) in guideline-directed care. Policy and reimbursement shifts have incentivized non-invasive diagnostic pathways; for example, coronary CT angiography utilization has accelerated in many U.S. health systems since guideline updates in the mid-2010s. Against that background, proprietary diagnostic algorithms that claim to reduce unnecessary invasive angiography represent both clinical and commercial leverage points for vendors and their hospital clients.

The clinical stakes are not abstract. Cardiovascular disease remains the leading cause of death in the United States, with approximately 697,000 deaths attributed to heart disease in 2020 (CDC, 2020). That morbidity and mortality burden drives demand for diagnostic precision, which in turn underpins the commercial value attached to advanced imaging analytics. For institutional stakeholders, the dispute between HeartFlow and Cleerly could influence hospital procurement choices, vendor consolidation dynamics, and the pace at which health systems integrate AI-augmented diagnostic tools into pathways for chest pain and stable CAD.

Data Deep Dive

Primary source material is limited to the complaint and press reporting at publication: Investing.com published the news on Apr 13, 2026 (Investing.com). The complaint reportedly alleges infringement tied to HeartFlow's diagnostic method claims; HeartFlow has historically commercialized a CT-derived FFR solution that models coronary blood flow, while Cleerly emphasizes automated plaque and stenosis quantification from coronary CT images. The technical overlap centers on post-processing pipelines—segmentation, 3D vessel modeling, physiological simulation and decision-support outputs—that are core to how both companies deliver clinically actionable scores to cardiologists and radiologists.

Quantitative indicators relevant to the dispute include adoption metrics and unit economics. Publicly available aggregate data indicate rising CCTA case volumes in tertiary centers: many U.S. health networks reported year-over-year increases in CCTA studies of 10–30% during the 2022–2025 window as non-invasive pathways expanded (internal hospital reports; industry surveys). These adoption trends increase the addressable volume for both HeartFlow-style and Cleerly-style products. Even modest differences in per-case reimbursement capture or accuracy can compound: a 5% reduction in unnecessary invasive coronary angiography across an institution performing 2,000 relevant CTAs annually could alter downstream procedural volumes by tens of cases and meaningfully affect hospital margins and vendor usage patterns.

From an IP-value perspective, the potential damages and injunctive relief claimed in patent suits can range significantly. While the current complaint does not specify public damage figures in press coverage, precedent in medtech patent litigation shows damages awards or settlements that have reached nine-figure levels in high-stakes cases, or conversely led to licensing agreements that preserved market access. For competitive dynamics, the more immediate impact is often on purchasing decisions and go-to-market planning: customers may pause platform-wide rollouts until legal clarity emerges, and payors may ask for additional evidence linking diagnostic outputs to clinical outcomes and cost-savings.

Sector Implications

The dispute highlights an emergent inflection point in diagnostic cardiology: algorithmic differentiation versus platform breadth. HeartFlow’s commercial narrative has emphasized physiology (FFRct) and downstream decision impact, while Cleerly’s pitch centers on detailed plaque phenotyping and automated reporting workflows. Clinicians evaluate both accuracy and workflow fit; thus, litigation that casts doubt on exclusivity claims or forces licensing deals could reallocate market share between vendors or accelerate consolidation among imaging analytics providers. For health systems, this raises procurement risk—selecting a narrowly differentiated solution versus an ecosystem partner that can offer multi-modality inputs.

Peer-group effects are also relevant. Vendors across imagery and AI-enabled diagnostics monitor this case because outcomes could set precedent on enforceability of algorithmic process patents. Large incumbents—imaging OEMs and established enterprise software vendors—could leverage uncertainty to upsell integrated solutions or negotiate cross-license agreements. Conversely, smaller innovators may face heightened IP scrutiny and transaction costs when entering hospital markets. For investors and corporate strategists, the litigation may recalibrate valuation premium attached to defensible IP in algorithmic medical devices.

Comparison to prior medtech litigation is instructive. High-profile patent disputes, for instance between diagnostic platform owners in the 2010s, often led to settlement-based licensing and targeted injunctions that preserved broader market access while extracting royalty streams. Year-over-year litigation frequency in life sciences has been uneven; however, the trend toward algorithmic IP disputes has grown as analytical methods become central to perceived product value. The HeartFlow–Cleerly suit could follow a similar arc—settlement, licensing, or protracted litigation—each with distinct implications for competitors, hospitals, and payors.

Risk Assessment

Legal outcomes are inherently uncertain and timeline-dependent. Typical U.S. patent litigation in district court can span multiple years, with interlocutory rulings on claim construction and potential stays pending inter partes review (IPR) at the Patent Trial and Appeal Board. For customers, the risk window for procurement disruption is the next 6–18 months; for investors, valuation impacts may crystallize only if an injunction or material damages award occurs. Operational risk for both companies includes engineering distraction, diverted commercial resources, and potential reputational costs among clinician customers.

Regulatory and reimbursement risk compounds legal uncertainty. Payers increasingly demand real-world evidence that diagnostic algorithms improve outcomes or reduce total cost of care. If litigation reduces a vendor’s ability to demonstrate scale—by impeding deployments or data collection—then payor negotiations and coverage determinations could be affected. Conversely, a resolved dispute that clarifies IP ownership could facilitate broader data-sharing agreements and bolster evidence-generation across competing platforms.

From a market-impact perspective, direct share-price effects are likely to be muted in the near term because both HeartFlow and Cleerly are private companies and no single public comparable is directly named in filings. That said, publicly traded peers in the imaging and medtech space could experience short-lived volatility if headlines suggest broader market disruption. We assess immediate market impact as limited but non-trivial for sector sentiment and procurement cycles.

Fazen Capital Perspective

Fazen Capital views this as a contest about the economics of proprietary analytics, not merely a debate over lines of code. The commercial value of diagnostic AI is anchored to two levers: (1) demonstrable clinical impact (reduction in unnecessary invasive procedures, improved patient triage) and (2) defensible, transactable IP that supports sustainable commercial margins. Litigation can impose a toll on both levers by distracting management, delaying rollouts, and creating temporary procurement headwinds. Yet it can also crystallize value: settlements and licensing deals frequently convert uncertain competitive advantage into recurring revenue streams.

We believe the more consequential outcome will be whether the case prompts health systems to prefer platform-agnostic standards and validated open benchmarks for CAD analytics. A contrarian read is that increased litigation risk could accelerate adoption of consortium-driven validation studies and interoperability standards—reducing vendor lock-in and shifting value from IP dominance to evidence-generation capability. Firms that can demonstrate outcomes across diverse populations and workflows, irrespective of proprietary processing stacks, may gain durable advantages even if they concede narrow patent claims.

For institutional stakeholders evaluating exposure or opportunity in the space, focus should be on operational metrics: per-case reimbursement capture, validated reductions in downstream procedures, and the scale of installed base across integrated health systems. Legal noise is temporary; economic differentiation tied to outcomes and integration is persistent. See our broader research on healthcare AI commercialization and vendor selection healthcare AI and diagnostic platform strategy diagnostics for frameworks and case studies.

FAQ

Q: Could this suit lead to an injunction that halts Cleerly’s product sales? A: Injunctions are possible but relatively rare without clear, irreparable harm and strong preliminary evidence—courts balance public interest in access to healthcare tools. Typical timelines for a preliminary injunction motion extend several months after filing, and orders can be stayed pending appeals or parallel IPR proceedings.

Q: What are practical implications for hospitals that have deployed either platform? A: Hospitals should review existing contracts for indemnities and licensing terms, assess contingency plans for vendor substitution, and accelerate outcomes tracking to ensure continued reimbursement. Procurement teams frequently include contractual clauses that mitigate IP risk and preserve clinical continuity; those clauses become more valuable after a filing.

Bottom Line

HeartFlow’s filing on Apr 13, 2026 elevates intellectual property as a decisive strategic battleground in cardiac imaging analytics; the near-term impact will be on procurement rhythms, evidence-generation, and competitive positioning rather than immediate market dislocation. Stakeholders should watch litigation timelines, payor responses, and shifts toward open validation frameworks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.